Literature DB >> 3729361

In vitro activity of Ro 15-8074 and Ro 19-5247, two orally administered cephalosporin metabolites.

R Wise, J M Andrews, L J Piddock.   

Abstract

The activity of two iminomethoxy aminothiazoly cephalosporins, Ro 15-8074 and Ro 19-5247, was compared with that of other beta-lactams against a total of 491 bacterial strains. Both were highly active (MIC for 90% of the strains tested [MIC 90], less than or equal to 2 micrograms/ml) against the majority of the members of the family Enterobacteriaceae, Haemophilus influenzae, Neisseria spp., and Streptococcus pneumoniae, being at least 16-fold more active than cephalexin and 8-fold more active than cefuroxime. There was no activity against Pseudomonas aeruginosa and poor activity against Morganella morganii (in the case of Ro 15-8074), Enterobacter sp., and Citrobacter sp. Staphylococcus aureus was moderately susceptible to Ro 19-5247 (MIC90, 8 micrograms/ml), but Ro 15-8074 was eightfold less active. The protein binding of the two compounds at 5 micrograms/ml was 9.1% for Ro 15-8074 and 69.9% for Ro 19-5247. The major target site for the two cephalosporins was PBP 3.

Entities:  

Mesh:

Substances:

Year:  1986        PMID: 3729361      PMCID: PMC180501          DOI: 10.1128/AAC.29.6.1067

Source DB:  PubMed          Journal:  Antimicrob Agents Chemother        ISSN: 0066-4804            Impact factor:   5.191


  12 in total

1.  Inhibition of Escherichia coli K-12 by beta-lactam antibiotics with poor antibacterial activity: interaction of permeability and intrinsic activity against penicillin-binding proteins.

Authors:  N A Curtis; C Brown; M Boxall; M G Boulton
Journal:  Antimicrob Agents Chemother       Date:  1979-03       Impact factor: 5.191

Review 2.  The beta-lactamases of gram-negative bacteria and their possible physiological role.

Authors:  M H Richmond; R B Sykes
Journal:  Adv Microb Physiol       Date:  1973       Impact factor: 3.517

3.  In vitro activity of Ro 15-8074, a new oral cephalosporin, against Neisseria gonorrhoeae.

Authors:  W S Ng; P Y Chau; Y K Leung; P C Wong
Journal:  Antimicrob Agents Chemother       Date:  1985-09       Impact factor: 5.191

4.  Porin-mediated cephalosporin resistance in Escherichia coli K-12.

Authors:  N A Curtis; R L Eisenstadt; K A Turner; A J White
Journal:  J Antimicrob Chemother       Date:  1985-05       Impact factor: 5.790

5.  The pharmacokinetics of orally absorbed cefuroxime compared with amoxycillin/clavulanic acid.

Authors:  R Wise; S A Bennett; J Dent
Journal:  J Antimicrob Chemother       Date:  1984-06       Impact factor: 5.790

6.  Comparative pharmacokinetics of cephalexin, cefaclor, cefadroxil, and CGP 9000.

Authors:  H Lode; R Stahlmann; P Koeppe
Journal:  Antimicrob Agents Chemother       Date:  1979-07       Impact factor: 5.191

7.  Properties of the penicillin-binding proteins of Escherichia coli K12,.

Authors:  B G Spratt
Journal:  Eur J Biochem       Date:  1977-01

8.  Role of porin proteins OmpF and OmpC in the permeation of beta-lactams.

Authors:  A Jaffe; Y A Chabbert; O Semonin
Journal:  Antimicrob Agents Chemother       Date:  1982-12       Impact factor: 5.191

9.  Comparative in vitro activity and beta-lactamase stability of FR 17027, a new orally active cephalosporin.

Authors:  H C Neu; N X Chin; P Labthavikul
Journal:  Antimicrob Agents Chemother       Date:  1984-08       Impact factor: 5.191

10.  Cefadroxil, a new broad-spectrum cephalosporin.

Authors:  R E Buck; K E Price
Journal:  Antimicrob Agents Chemother       Date:  1977-02       Impact factor: 5.191

View more
  25 in total

1.  In vitro susceptibility of Haemophilus influenzae to cefaclor, cefixime, cefetamet and loracarbef.

Authors:  J D Williams; M Powell; Y S Fah; A Seymour; M Yuan
Journal:  Eur J Clin Microbiol Infect Dis       Date:  1992-08       Impact factor: 3.267

2.  Pharmacokinetics of intravenous cefetamet (Ro 15-8074) and oral cefetamet pivoxil (Ro 15-8075) in young and elderly subjects.

Authors:  R A Blouin; J Kneer; K Stoeckel
Journal:  Antimicrob Agents Chemother       Date:  1989-03       Impact factor: 5.191

3.  Comparative in vitro activity of the two new oral cephalosporin metabolites RO 19-5247 and RO 15-8074.

Authors:  K E Aldridge; D D Schiro; C V Sanders
Journal:  Eur J Clin Microbiol       Date:  1987-10       Impact factor: 3.267

4.  In vitro activity of the two new oral cephalosporins RO 15-8074 and RO 19-5247.

Authors:  E Stobberingh; A W Houben; C P van Boven
Journal:  Eur J Clin Microbiol       Date:  1987-08       Impact factor: 3.267

5.  Preliminary antimicrobial susceptibility interpretive criteria for cefetamet (Ro 15-8074) and cefteram (Ro 19-5247) disk tests.

Authors:  R N Jones; A L Barry
Journal:  J Clin Microbiol       Date:  1987-09       Impact factor: 5.948

Review 6.  Cefetamet pivoxil. A review of its antibacterial activity, pharmacokinetic properties and therapeutic use.

Authors:  H M Bryson; R N Brogden
Journal:  Drugs       Date:  1993-04       Impact factor: 9.546

7.  Antimicrobial activity and disk diffusion susceptibility testing of U-76,253A (R-3746), the active metabolite of the new cephalosporin ester, U-76,252 (CS-807).

Authors:  R N Jones; A L Barry
Journal:  Antimicrob Agents Chemother       Date:  1988-04       Impact factor: 5.191

8.  Pharmacokinetics of cefetamet (Ro 15-8074) and cefetamet pivoxil (Ro 15-8075) after intravenous and oral doses in humans.

Authors:  J R Koup; U C Dubach; R Brandt; R Wyss; K Stoeckel
Journal:  Antimicrob Agents Chemother       Date:  1988-04       Impact factor: 5.191

9.  Comparative in vitro activity of cefetamet (RO 15-8074).

Authors:  K Machka; I Braveny
Journal:  Eur J Clin Microbiol       Date:  1987-08       Impact factor: 3.267

Review 10.  Cefetamet pivoxil clinical pharmacokinetics.

Authors:  R A Blouin; K Stoeckel
Journal:  Clin Pharmacokinet       Date:  1993-09       Impact factor: 6.447

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.